CA
IRMD icon

Clearstead Advisors’s iRadimed IRMD Stock Holding History

Clearstead Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.31K Buy
87
+38
+78% +$3.46K ﹤0.01% 2045
2026
Q1 		$4.72K Hold
49
– – ﹤0.01% 1748
2025
Q4 		$4.77K Hold
49
– – ﹤0.01% 2028
2025
Q3 		$3.49K Buy
+49
New +$3.27K ﹤0.01% 2289
2025
Q1 		– Sell
-178
Closed -$9.79K – 2258
2024
Q4 		$9.79K Buy
178
+10
+6% +$526 ﹤0.01% 1568
2024
Q3 		$8.45K Buy
168
+49
+41% +$2.26K ﹤0.01% 1616
2024
Q2 		$5.23K Buy
119
+7
+6% +$298 ﹤0.01% 1683
2024
Q1 		$4.75K Buy
112
+58
+107% +$2.56K ﹤0.01% 1183
2023
Q4 		$2.56K Buy
+54
New +$2.27K ﹤0.01% 1253

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Clearstead Advisors's IRMD Position: Q2 2026 in Review

Clearstead Advisors increased its iRadimed (IRMD) stake by 78% in Q2 2026, buying an estimated $3.46K and bringing the position to 87 shares worth $8.31K. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

Clearstead Advisors first reported a position in IRMD in Q4 2023 and has held it in 9 quarters since. The position peaked at $9.79K in Q4 2024. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Clearstead Advisors held 87 shares of iRadimed worth $8.31K as of Q2 2026.
  • Clearstead Advisors bought 38 iRadimed shares in Q2 2026, an estimated $3.46K.
  • iRadimed made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2045 holding.
  • Clearstead Advisors first reported a position in iRadimed in Q4 2023 and has held it in 9 quarters since.
  • Clearstead Advisors's iRadimed position peaked at $9.79K in Q4 2024.
  • 214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.